Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sofosbuvir + velpatasvir + elbasvir + grazoprevir
- Development stage
- Unknown
- Lead developer
- Gilead Sciences
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
This is a non-standard, theoretical combination of two fixed-dose antiviral hepatitis C therapies—Epclusa (sofosbuvir/velpatasvir) and Zepatier (elbasvir/grazoprevir). Each product is itself a combination of direct-acting antivirals targeting different proteins essential for hepatitis C virus (HCV) replication. Sofosbuvir is an NS5B RNA-dependent RNA polymerase inhibitor, velpatasvir and elbasvir are NS5A inhibitors, and grazoprevir is an NS3/4A protease inhibitor. These agents act synergistically to inhibit HCV replication at multiple stages of the viral life cycle. Epclusa covers all six major HCV genotypes, while Zepatier targets genotypes 1 and 4[2][3][5]. There are no clinical guidelines or approvals for using both combinations together.
- Brand names
- EpclusaZepatier
- Other names
- Epclusa + Zepatier
02
Targets
NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))
Beyond the preview
Go deeper on sofosbuvir + velpatasvir + elbasvir + grazoprevir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sofosbuvir + velpatasvir + elbasvir + grazoprevir.